Who is sponsoring NCT05726526?

NCT05726526 is sponsored by University of Manitoba.

What drugs are being tested in NCT05726526?

Interventions in NCT05726526: VIEWER virtual care platform.

What condition does NCT05726526 study?

NCT05726526 studies Chronic Kidney Disease Stage 5, End Stage Renal Disease.

Is NCT05726526 still recruiting?

NCT05726526 is currently recruiting now. Last updated 9 March 2026.

Last reviewed 2026-03-09 · How we verify

NCT05726526: VIEWER

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CKD Specific Telemonitoring Platform to Minimize Adverse Outcomes in High Risk CKD Patients

Recruiting now NA Last updated 9 March 2026

What this trial tests

NA trial testing VIEWER virtual care platform in Chronic Kidney Disease Stage 5 in 340 participants. Currently enrolling.

Timeline

30 June 2022

Primary endpoint
30 March 2027

30 March 2028

Quick facts

Lead sponsor	University of Manitoba
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	supportive care
Enrollment	340
Start date	30 June 2022
Primary completion	30 March 2027
Estimated completion	30 March 2028
Sites	5 locations across Canada

Drugs / interventions tested

VIEWER virtual care platform

Conditions studied

Chronic Kidney Disease Stage 5 — all drugs for Chronic Kidney Disease Stage 5 →
End Stage Renal Disease — all drugs for End Stage Renal Disease →

Sponsor

University of Manitoba

Who can join

18 and older, any sex, with Chronic Kidney Disease Stage 5 or End Stage Renal Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main purpose of this trial is to determine whether the addition of the VIEWER virtual care platform to usual care will lead to a reduction in composite emergency department (ED) visits and/or hospitalizations/or increase the perceived safety of virtual care among patients and providers.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

A Pragmatic Randomized Controlled Trial of a CKD-Specific Virtual Monitoring Platform to Minimize Adverse Outcomes in High-Risk CKD Patients: A Clinical Research Protocol.
Solati Z, Komenda P, Tangri N, Saul S, et al · · 2025 · PMID 41058978 · DOI 10.1177/20543581251359736

Verify or expand the search:

Other recruiting trials for Chronic Kidney Disease Stage 5

Currently open trials in the same condition.

NCT06982079 — Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Kidney Function in Advanced Chronic Kidney Disease · Phase 3 · recruiting
NCT06799936 — A Communication-Priming Intervention to Improve Shared Decision-Making Between Older Adults With Advanced CKD and Clinic · NA · recruiting
NCT06542016 — An Evaluation of the KCCQ Score in Predicting Cardiovascular Risk in Dialysis Patients · recruiting

Other University of Manitoba trials

Trials by the same sponsor.

NCT07528417 — Evaluation of Antibiotic Prophylaxis in Myelodysplastic Syndromes and Acute Myeloid Leukemia (MYELO-CAN:ABX) · Phase 2 · not yet recruiting
NCT07366515 — Feasibility of a Multimodal Virtual Reality Intervention to Reduce Preoperative Anxiety in Cancer Surgery Patients · NA · not yet recruiting
NCT07354386 — Effects of Dried Whole Fruits on Metabolism in Diabetes · NA · enrolling by invitation
NCT07361315 — Development and Online Evaluation of an Online Course for Parasomnias · NA · recruiting
NCT07023744 — CANnabinoids for Drug Resistant Epilepsy (DRE) in Adults and Children · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05726526 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Manitoba
Last refreshed: 9 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05726526.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing